nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
== Biography == Woodroof was born in Dallas, Texas, on February 3, 1950, to Garland Odell Woodroof (March 17, 1917, in Texas – December 3, 1983, in Dallas) and Willie Mae Hughes (November 25, 1917, in Oklahoma – November 19, 1996, in Dallas). His first marriage was to Mary Etta Pybus on June 28, 1969, in Dallas; they had a daughter. They divorced on March 23, 1972. On May 6, 1972, he married a woman named Rory S. Flynn in Dallas. They divorced on May 21, 1973. He then married Brenda Shari Robin on October 4, 1982, in Lubbock. They divorced on March 4, 1986, after he was diagnosed with HIV. It was recorded that Woodroof had a mercurial personality. One reporter writes that "Woodroof took guns to his doctor’s office, prompting Steven Pounders to 'fire him as a patient.'" Woodroof later sent the doctor roses, and the doctor took him back. Woodroof was said to have lost all his friends after they found out he was HIV-positive. The movie Dallas Buyers Club depicts Woodroof as holding homophobic views prior to contracting HIV. Other people who knew Woodroof said that he did not harbor anti-gay beliefs and was openly bisexual. He was a member of the Dallas Gay Alliance.
==== As prophylaxis against sexually transmitted infections ==== Doxycycline is used as post-exposure prophylaxis (PEP) to prevent certain sexually transmitted infections, known as doxycycline post-exposure prophylaxis (doxyPEP). A landmark randomized trial in San Francisco found that a single 200 mg dose of doxycycline taken within 72 hours after condomless sex reduced the overall incidence of bacterial STIs by approximately two-thirds among men who have sex with men (MSM) and transgender women, with reductions of 87–88% for chlamydia, 73–87% for syphilis, and 55% for gonorrhea. However, a separate trial found doxyPEP was not effective in cisgender women. In June 2024, the US Centers for Disease Control and Prevention (CDC) issued clinical guidelines recommending doxyPEP for MSM and transgender women with at least one bacterial STI in the prior 12 months. The Australasian Society for HIV Medicine issued a more cautious consensus statement recommending doxyPEP only for syphilis prevention in MSM, citing concerns that the risk of increasing antimicrobial resistance, especially in Neisseria gonorrhoeae, outweighed the benefits for other STIs. Use of doxyPEP has been associated with tetracycline resistance in N. gonorrhoeae.
== Additional biological roles == Stress-induced adrenal hormone increase may upregulate GnIH release, as some GnIH neurons have adrenal glucocorticoid receptors. GnIH may therefore mediate interactions between the HPG and HPA (hypothalamic-pituitary-adrenal) axes and play a role in stress-related infertility. GnIH neurons of the paraventricular nucleus in the hypothalamus also express melatonin receptors. Because melatonin secretion is modulated by environmental light patterns, melatonin influence on GnIH production may enable photoperiodic regulation of reproduction in seasonally breeding birds, rodents, and sheep. GnIH increases food consumption, implying a role in appetite. This finding is consistent with the location of most GnIH neurons, as the dorsomedial nucleus of the hypothalamus is involved in appetite regulation. GnIH may allow the energy reserves of an organism to modulate reproduction. Higher levels of thyroid hormone suppress GnIH expression, and lower levels of thyroid hormone are associated with higher GnIH levels. The inactivation of GnIH expression prevents delayed puberty caused by hypothyroidism, demonstrating that GnIH mediates interactions between the HPG and HPT (hypothalamic-pituitary-thyroid) axes. Furthermore, thyroid hormone may function in a pathway for photoperiodic regulation of reproduction involving GnIH and energy status. Melatonin modulates thyroid-stimulating hormone (TSH) production in the anterior pituitary, and TSH promotes thyroid hormone production.
=== Spectrum of activity === Like other third-generation cephalosporins, ceftriaxone is active against Citrobacter spp., Serratia marcescens, and beta-lactamase-producing strains of Haemophilus and Neisseria. However, unlike ceftazidime and cefoperazone, ceftriaxone does not have useful activity against Pseudomonas aeruginosa. It is generally not active against Enterobacter species, and its use should be avoided in the treatment of Enterobacter infections, even if the isolate appears susceptible, because of the emergence of resistance. Some organisms, such as Citrobacter, Providencia, and Serratia, have the ability to become resistant through the development of cephalosporinases (enzymes that hydrolyze cephalosporins and render them inactive). Although not being used as first line therapy against Staphylococcus aureus, ceftriaxone retains activity against isolates of methicillin-susceptible S. aureus and is used in clinic for infections sustained by this bacterium. In this case the dose should be doubled (e.g. 2 g intravenously every 12 hours).
Sources: en.wikipedia.org
In 2019, Dream Market was the most popular market by far, with over 120,000 current trade listings, followed at one time by Wall Street Market with under 10,000 listings. Dream Market was shut down in 2019, and Wall Street Market was seized by law enforcement in May 2019 as part of an Internal Law Enforcement Operation Dark Huntor. That same operation also shut down the dark markets DeepSea, Berlusconi, White House, and Dark Market. The May 2019 seizure of news and links site DeepDotWeb for conspiring with the markets created a temporary disruption around market navigation. In 2021, authorities took down the dark web marketplace DarkMarket, along with arresting the Australian man who was believed to be the operator of the website. The 20 servers that hosted the website were seized. In August 2021, AlphaBay was relaunched after the return of one of the original security administrators DeSnake. In June 2025, Europol took down the Archetyp Market with an estimated 3200 registered vendors and 600,000 customers worldwide.
In 2023, LECO and Cal State LA worked in tandem to launch a new chemical analysis lab. The new lab would work with both undergraduate and graduate students within the Department of Chemistry and Biochemistry. Since 2025, the cement industry has been working to reduce carbon emissions and adopt more sustainable production methods. The LECO Corporation provides analytical instrumentation to support that transition. Its portfolio has included calorimeters, thermogravimetric analyzers, and combustion analyzers that measure factors such as calorific value, moisture, ash, carbon, sulfur, and loss on ignition in fuels and raw materials. This helps cement producers evaluate alternative inputs, monitor performance, and improve operational efficiency while reducing environmental impact. Research was also conducted at Oxford by scholars within the Department of Materials which tested the LECO process of testing solar cells and silicon materials.
On December 13, 2018, the teaser of the film Black Antenna featuring the song "Rainier Fog" was released on Alice in Chains' official YouTube channel, with drummer Sean Kinney stating; "We've always toyed with the idea of creating videos for every song on one of our albums. Not only did we do that for Rainier Fog, it got totally out of hand and we made a whole goddamn movie. Everything that will be seen in the videos will be footage from Black Antenna to preface the complete film's release." "Rainier Fog" was released as a single on February 26, 2019. The official trailer for Black Antenna was released on Alice in Chains' YouTube Channel on February 28, 2019. Besides a 90-minute film, a 10-part web-series focused on each track from the album was planned. Episodes 1 and 2, "The One You Know" and "Rainier Fog", respectively, were released on March 7, 2019. The tenth and last episode, "All I Am", was released on July 17, 2019. The official music video for "Rainier Fog" was released on YouTube on May 15, 2019, and was co-directed by Alice in Chains and Peter Darley Miller, who also directed the band's 2013 mockumentary, AIC 23. On December 1, 2020, Alice in Chains was honored with the Founders Award from Seattle's Museum of Pop Culture. The benefit concert featured tribute performances from artists such as Ann Wilson, Korn, Metallica, Fishbone, Dallas Green, Billy Corgan, Tad Doyle, members of Soundgarden and Pearl Jam, among others. The event was made available for streaming for free and raised more than $600,000 for the museum in its first night.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.